Press Releases

Everest Medicines to Announce Half-Year 2021 Interim Results

Everest Medicines Announces Approval of Clinical Trial Application by China NMPA for Phase 3 Trial of XeravaTM for Community-Acquired Bacterial Pneumonia

Everest Medicines Receives Pediatric and Rare Severe Disease Priority Review Designation from Taiwan FDA for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer

Everest Medicines Announces Strategic Collaboration with MediTrust Health Co., Ltd to Develop Novel Payment Solutions for Patients in China

Everest Medicines Announces Strategic Collaboration with Medbanks Health Technology to Develop Innovative Healthcare Service Solutions for Patients in China

Everest Medicines Announces Strategic Commercial Partnership with Global Technology Company, Tencent

Everest Medicines Announces that Spero Therapeutics Entered into Licensing Agreement with Pfizer Inc. for SPR206 in ex-U.S. and ex-Asia Territories

Everest Medicines Announces China NMPA Has Granted Priority Review for Sacituzumab Govitecan-hziy in Metastatic Triple-Negative Breast Cancer

Everest Medicines Announces China NMPA Has Accepted Biologics License Application for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer

Everest Medicines Receives Orphan Drug Designation from the Ministry of Food and Drug Safety in South Korea for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer

Everest Medicines Appoints Jennifer Yang as Chief Scientific Officer

Everest Medicines Announces that the US FDA has Granted Licensing Partner Gilead Sciences, Inc. Accelerated Approval of Trodelvy® for the Treatment of Metastatic Urothelial Cancer

Everest Medicines Announces that Licensing Partner Gilead Sciences, Inc. has Received Full US FDA Approval of Trodelvy® for the Treatment of Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

Everest Medicines Announces China NMPA Approval of Clinical Trial Application to Evaluate Trodelvy® in a Phase 2 Basket Trial for a Variety of Cancers with High TROP-2 Expression

Everest Medicines Announces Financial Results for Full Year Ended December 31, 2020

Everest Medicines Announces Acceptance of New Drug Application by China NMPA for Xerava™ for the Treatment of Complicated Intra-abdominal Infections

Everest Medicines to Announce Full-Year 2020 Financial Results on March 22, 2021

Everest Medicines Announces Selection as a Constituent of Certain Indexes of Hang Seng Indexes Company Limited

Everest Medicines Appoints Kevin Guo as Chief Commercial Officer

Everest Medicines CEO Awarded the 13th Health China Top 10 Pharmaceutical Business Leaders Award